as 11-14-2024 1:30pm EST
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Founded: | 2010 | Country: | United Kingdom |
Employees: | N/A | City: | N/A |
Market Cap: | 9.8M | IPO Year: | 2018 |
Target Price: | N/A | AVG Volume (30 days): | 25.7K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.62 | EPS Growth: | N/A |
52 Week Low/High: | $1.09 - $17.49 | Next Earning Date: | 12-20-2024 |
Revenue: | $431,378 | Revenue Growth: | -66.71% |
Revenue Growth (this year): | 157729.1% | Revenue Growth (next year): | -78.44% |
APM Breaking Stock News: Dive into APM Ticker-Specific Updates for Smart Investing
Business Wire
7 months ago
Business Wire
8 months ago
GlobeNewswire
10 months ago
GlobeNewswire
10 months ago
GlobeNewswire
10 months ago
Zacks Small Cap Research
10 months ago
GlobeNewswire
10 months ago
PR Newswire
a year ago
The information presented on this page, "APM Aptorum Group Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.